Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | ACACB | O00763 | 4/20 | 0.44 |
| ▸ | GHSR | Q92847 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892078 | 0.92 | CYP3A4 (0.48) | CYP1A2CYP2C9CYP2C19USP2ALDH1A1 | |
| SCHEMBL16892030 | 0.91 | ACACB (0.44) | CYP1A2CYP2C9CYP2C19USP2ALDH1A1 | |
| SCHEMBL20311305 | 0.90 | ACACB (0.47) | CYP1A2CYP2C9CYP2C19USP2ALDH1A1 | |
| SCHEMBL16891998 | 0.90 | RORC (0.47) | OPRD1OPRK1RORCACACBCYP11B2 | |
| SCHEMBL31161858 | 0.89 | CYP1A2 (0.45) | CYP1A2CYP2C9CYP2C19USP2ALDH1A1 | |
| SCHEMBL16892052 | 0.86 | VEGFA (0.50) | — | |
| SCHEMBL20528288 | 0.84 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19USP2ALDH1A1 | |
| SCHEMBL27477846 | 0.83 | CYP2D6 (0.62) | CYP1A2CYP2C9CYP2C19USP2ALDH1A1 | |
| SCHEMBL28644780 | 0.83 | GHSR (0.57) | CYP1A2CYP2C9CYP2C19USP2ALDH1A1 | |
| SCHEMBL31458848 | 0.83 | GHSR (0.57) | CYP1A2CYP2C9CYP2C19USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-3091008-B1 | KINASE INHIBITOR AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| EP-3091008-B1 | KINASE INHIBITOR AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-9949976-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-9949976-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-9949976-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20180000819-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2018-01-04 | — | — | US | disclosed |
| US-20180000819-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2018-01-04 | — | — | US | disclosed |
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2016-11-17 | — | — | US | disclosed |
| EP-3091008-A1 | KINASE INHIBITOR AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015101293-A1 | KINASE INHIBITOR AND USE THEREOF | 山东轩竹医药科技有限公司 | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332989-A1 | Kinase Inhibitor And Use Thereof | CDK4, CDK6, CDK3 | CYP1A2 4084/4885CYP2C9 2310/4885CYP2C19 2274/4885 |
| US-20180000819-A1 | KINASE INHIBITOR AND USE THEREOF | CDK4, CDK6, CDK3 | CYP1A2 4084/4885CYP2C9 2310/4885CYP2C19 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.